Search

Displaying results 3261 - 3270 of 10000 in total
  1. Drug

    Vusolimogene oderparepvec

    go.drugbank.com/drugs/DB23008
    ApprovedInvestigational

    [L64061,L64062] It is the second oncolytic viral therapy approved in the United States, following talimogene laherparepvec (T-VEC, Imlygic) in 2015, and the first approved for melanoma that has progressed … Vusolimogene oderparepvec-wtpg is a genetically modified herpes simplex virus type 1 (HSV-1) oncolytic viral therapy used, in combination with [nivolumab], to treat advanced melanoma.

  2. Drug

    Zalcitabine

    go.drugbank.com/drugs/DB00943
    ApprovedWithdrawn

    Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy. … A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen.

  3. Drug

    Lutein

    go.drugbank.com/drugs/DB00137
    ApprovedNutraceutical

    Lutein is synthesized only by plants and like other xanthophylls is found in high quantities in green leafy vegetables such as spinach, kale and yellow carrots. … In green plants, xanthophylls act to modulate light energy and serve as non-photochemical quenching agents to deal with triplet chlorophyll (an excited form of chlorophyll), which is overproduced at very

  4. Drug

    Cyclandelate

    go.drugbank.com/drugs/DB04838
    ApprovedWithdrawn

    It may cause gastrointestinal distress and tachycardia. Cyclandelate is not approved for use in the U.S. or Canada, but is approved in various European countries.

  5. Drug

    Phenacemide

    go.drugbank.com/drugs/DB01121
    Approved

    Phenacemide is used to control certain seizures in the treatment of epilepsy. This medicine acts on the central nervous system (CNS) to reduce the number and severity of seizures.

  6. Drug

    Lumiracoxib

    go.drugbank.com/drugs/DB01283
    ApprovedWithdrawn

    New Zealand and Canada have also followed suit in recalling the drug. … On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver

  7. Drug

    Brotizolam

    go.drugbank.com/drugs/DB09017
    ApprovedWithdrawn

    Brotizolam is not approved for sale in the UK, United States or Canada but is sold in the Netherlands, Germany, Spain, Belgium, Austria, Portugal, Israel, Italy and Japan. … Brotizolam is an extremely potent drug and it is rapidly eliminated with an average half-life of 4.4 hours (range 3.6 - 7.9 hours).

  8. Drug

    Diethylstilbestrol

    go.drugbank.com/drugs/DB00255
    ApprovedWithdrawn

    A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. … According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen.

  9. Drug

    Pegsunercept

    go.drugbank.com/drugs/DB06611
    Investigational

    Pegsunercept is used for treating rheumatoid arthritis. Phase II clinical trials were completed in January 2010.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Pentostatin

    go.drugbank.com/drugs/DB00552
    ApprovedInvestigational

    The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. … It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.